Trials continue
http://nocache.corpo...&item_id=854392
LongeCityAdvocacy & Research for Unlimited Lifespans
ALT 177 closer to approval?
Started by
caver
, May 12 2006 02:03 AM
5 replies to this topic
#3
- Topic Starter
-
- Guest
- 45 posts
- 0 ₮
- Location:St. Louis, MO, USA
Posted 12 May 2006 - 03:48 AM
On April 19, 2006, HaptoGuard, a privately-held company, announced a definitive merger agreement with Alteon Inc. (Amex: ALT). Alteon and HaptoGuard have complementary products under development in cardiovascular diseases and diabetes, including two Phase 2 clinical-stage compounds, ALT- 2074 (formerly known as BXT-51072) and alagebrium. Data is expected around year-end 2006 from a Phase 2 trial of HaptoGuard's ALT-2074 seeking to reduce myocardial injury in diabetic patients undergoing angioplasty or similar interventions. Alteon's alagebrium, which has been shown to improve cardiac function including the ability to significantly reduce left ventricular mass, is being developed for heart failure. The merger is subject to the approval of Alteon and HaptoGuard shareholders and is expected to close in the third quarter of 2006.
#5
-
- Guardian Reason
- 1,101 posts
- 272 ₮
- Location:US
Posted 12 May 2006 - 04:45 AM
No, looks like two separate but similar compounds?
http://www.biospace....ID=17582&full=1
"Alteon and HaptoGuard have complementary products under development in cardiovascular diseases and diabetes, including two Phase 2 clinical-stage compounds, BXT-51072 and alagebrium. Data is expected around year-end 2006 from two Phase 2 trials of HaptoGuard's BXT-51072 for reduction of mortality in post-myocardial infarction patients with diabetes. Alteon's alagebrium, which has been shown to improve cardiac function including the ability to significantly reduce left ventricular mass, is being developed for heart failure. The merger and stock conversion transactions are subject to the approval of Alteon and HaptoGuard shareholders and are expected to close in the third quarter of 2006."
http://www.biospace....ID=17582&full=1
"Alteon and HaptoGuard have complementary products under development in cardiovascular diseases and diabetes, including two Phase 2 clinical-stage compounds, BXT-51072 and alagebrium. Data is expected around year-end 2006 from two Phase 2 trials of HaptoGuard's BXT-51072 for reduction of mortality in post-myocardial infarction patients with diabetes. Alteon's alagebrium, which has been shown to improve cardiac function including the ability to significantly reduce left ventricular mass, is being developed for heart failure. The merger and stock conversion transactions are subject to the approval of Alteon and HaptoGuard shareholders and are expected to close in the third quarter of 2006."
#6
-
- Guest
- 464 posts
- 12 ₮
- Location:Switzerland
Posted 23 July 2006 - 11:07 AM
" The newly-combined company has two products in Phase 2 clinical development:
- ALT-2074 is HaptoGuard's licensed lead compound, a glutathione
peroxidase mimetic in development for reduction of mortality in
post-myocardial infarction patients with diabetes. The compound has
demonstrated the ability to reduce infarct size by approximately 85
percent in a mouse model of heart attack called ischemia reperfusion
injury. A Phase 2 clinical study for this compound is currently open
for enrollment. Additionally, HaptoGuard owns a license to a
proprietary genetic biomarker that has shown the potential to identify
patients who may be most responsive to the HaptoGuard compound.
"
- ALT-2074 is HaptoGuard's licensed lead compound, a glutathione
peroxidase mimetic in development for reduction of mortality in
post-myocardial infarction patients with diabetes. The compound has
demonstrated the ability to reduce infarct size by approximately 85
percent in a mouse model of heart attack called ischemia reperfusion
injury. A Phase 2 clinical study for this compound is currently open
for enrollment. Additionally, HaptoGuard owns a license to a
proprietary genetic biomarker that has shown the potential to identify
patients who may be most responsive to the HaptoGuard compound.
"
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
